Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism
| Autor: | Habibeh Yekehtaz, Nourrollah Yadegari, Mehdi Farokhnia, Mohammad Reza Mohammadi, Shahin Akhondzadeh, Omid Mirshafiee, Elmira Hassanzadeh |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Dopamine Agents Placebo-controlled study Placebo law.invention Double-Blind Method Randomized controlled trial law Internal medicine Amantadine medicine Humans Pharmacology (medical) Autistic Disorder Child Psychiatry Pharmacology Risperidone business.industry medicine.disease Irritable Mood Clinical trial Treatment Outcome Child Preschool Adjunctive treatment Dopamine Antagonists Autism Drug Therapy Combination Female Neurology (clinical) business medicine.drug |
| Zdroj: | Clinical Neuropharmacology. 36:179-184 |
| ISSN: | 0362-5664 |
| DOI: | 10.1097/wnf.0b013e3182a9339d |
| Popis: | Objective This study aimed to investigate the effect of adding amantadine to risperidone for treatment of autism. Methods Forty outpatients aged 4 to12 years, who were diagnosed with autism spectrum disorders based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, were assigned to this double-blind clinical trial. The subjects were divided randomly into 2 groups. One group received risperidone plus amantadine, and the other group received risperidone plus placebo. The dose of risperidone was titrated between 1 and 2.0 mg/d, and the dose of amantadine was 100 or 150 mg/d for patients less than 30 kg or more than 30 kg, respectively. The patients were assessed using the Aberrant Behavioral Checklist-Community (ABC-C) and adverse effects checklist as well as clinical global impression-improvement (CGI-I) at2 checkpoints of 5-week intervals after the baseline. Informed consentwas obtained from the parents of each participant. Results Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group. There was no significant difference in adverse effects between the 2 groups. The CGI-I scores show significant improvement in the amantadine group compared to the placebo group. Conclusions The present study suggests that amantadine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|